[go: up one dir, main page]

WO2005080418A3 - Inhibiteurs de fusion du vih multimerises - Google Patents

Inhibiteurs de fusion du vih multimerises Download PDF

Info

Publication number
WO2005080418A3
WO2005080418A3 PCT/DK2005/000121 DK2005000121W WO2005080418A3 WO 2005080418 A3 WO2005080418 A3 WO 2005080418A3 DK 2005000121 W DK2005000121 W DK 2005000121W WO 2005080418 A3 WO2005080418 A3 WO 2005080418A3
Authority
WO
WIPO (PCT)
Prior art keywords
multimerised
fusion proteins
fusion inhibitors
hiv fusion
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2005/000121
Other languages
English (en)
Other versions
WO2005080418A2 (fr
Inventor
Michael Etzerodt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Bio Denmark AS
Original Assignee
Roche Bio Denmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Bio Denmark AS filed Critical Roche Bio Denmark AS
Priority to EP05706783A priority Critical patent/EP1720899A2/fr
Priority to BRPI0507949-7A priority patent/BRPI0507949A/pt
Priority to US11/064,115 priority patent/US20050202043A1/en
Publication of WO2005080418A2 publication Critical patent/WO2005080418A2/fr
Publication of WO2005080418A3 publication Critical patent/WO2005080418A3/fr
Anticipated expiration legal-status Critical
Priority to US12/015,493 priority patent/US20100048879A1/en
Priority to US12/420,680 priority patent/US20100028995A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des protéines de fusion multimère présentant une activité antivirale. Ces protéines de fusion comprennent la région HR2 de l'ectodomaine de la protéine gp41 du virus de l'immunodéficience humaine qui est fusionnée à un peptide domaine de multimérisation tel qu'un domaine de trimérisation dérivé d'une tétranectine. Les protéines de fusion multimérisées peuvent être utilisées en tant qu'inhibiteurs de fusion du VIH pour le traitement du SIDA.
PCT/DK2005/000121 2004-02-23 2005-02-23 Inhibiteurs de fusion du vih multimerises Ceased WO2005080418A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP05706783A EP1720899A2 (fr) 2004-02-23 2005-02-23 Inhibiteurs de fusion du vih multimerises
BRPI0507949-7A BRPI0507949A (pt) 2004-02-23 2005-02-23 inibidores de fusão de hiv multimerizados
US11/064,115 US20050202043A1 (en) 2004-02-23 2005-02-23 Multimerised HIV fusion inhibitors
US12/015,493 US20100048879A1 (en) 2004-02-23 2008-01-16 Multimerised hiv fusion inhibitors
US12/420,680 US20100028995A1 (en) 2004-02-23 2009-04-08 Tetranectin Trimerizing Polypeptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54620004P 2004-02-23 2004-02-23
US60/546,200 2004-02-23
DKPA200400283 2004-02-23
DKPA200400283 2004-02-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/064,115 Continuation US20050202043A1 (en) 2004-02-23 2005-02-23 Multimerised HIV fusion inhibitors

Publications (2)

Publication Number Publication Date
WO2005080418A2 WO2005080418A2 (fr) 2005-09-01
WO2005080418A3 true WO2005080418A3 (fr) 2005-09-22

Family

ID=34888853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000121 Ceased WO2005080418A2 (fr) 2004-02-23 2005-02-23 Inhibiteurs de fusion du vih multimerises

Country Status (3)

Country Link
EP (1) EP1720899A2 (fr)
BR (1) BRPI0507949A (fr)
WO (1) WO2005080418A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143276A1 (en) * 2007-10-08 2009-06-04 Anaphore, Inc. Trimeric IL-1Ra
GB0422439D0 (en) * 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
EP2121743B1 (fr) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Substances thérapeutiques à base de protéines modifiées ciblées sur des récepteurs de tyrosine kinases, dont l'igf-ir
EP2117576B1 (fr) 2007-02-08 2014-04-16 University Of Utah Research Foundation Procédés et compositions apparentés à l'inhibition d'une entrée virale
CA2701705A1 (fr) * 2007-10-08 2009-04-16 Anaphore, Inc. Il-1ra trimerique
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
JP6205345B2 (ja) 2011-03-28 2017-09-27 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション ウイルス侵入の阻害に関する方法および組成物
EP3399994B1 (fr) 2016-01-07 2020-09-16 Navigen, Inc. Inhibiteurs de peptide d de pénétration du vih et leurs méthodes d'utilisation
WO2023039242A2 (fr) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Compositions de particules d'interféron multivalentes et procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013165A1 (fr) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polypeptide t1249 pegyle

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013165A1 (fr) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Polypeptide t1249 pegyle

Also Published As

Publication number Publication date
WO2005080418A2 (fr) 2005-09-01
BRPI0507949A (pt) 2007-07-24
EP1720899A2 (fr) 2006-11-15

Similar Documents

Publication Publication Date Title
WO2020252393A8 (fr) Compositions et procédés pour le traitement du virus de l'immunodéficience humaine
WO2008118849A3 (fr) Inhibiteurs de la protéase du vih-1
WO2005080418A3 (fr) Inhibiteurs de fusion du vih multimerises
UA115436C2 (uk) Протираковий злитий протеїн
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
WO2012012352A3 (fr) Peptides et protéines modifiés
WO2013006688A3 (fr) Immunogènes gp120 à extrémité n-terminale délétée
NZ598834A (en) Prevention, treatment and diagnosis of P. gingivalis infection
CL2004000648A1 (es) FASE CRISTALINA A Y B DEL ACIDO CICLOPROPA[E]PIRROLO[1,2,a]DIAZACICLOPENTADECINO-14a(5H)-CARBOXILICO-6-[[(CICLOPENTILOXI)CARBONIL]AMINO]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-TETRADECAHIDRO-2-[[7-METOXI-2-[2-[(1-METILETIL)AMINO]-4-TIAZOLIL]-4-QUINOLIN
WO2008103380A3 (fr) Compositions contre le virus de l'hépatite b, et procédés d'utilisation
WO2010022740A3 (fr) Polypeptides d’enveloppe du vih-1 pour un vaccin contre le vih
AR029810A1 (es) Metodos y composiciones para la inhibicion de los acontecimientos asociados con la fusion de membrana, incluyendo la transmision de rsv
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
WO2010041241A3 (fr) Peptides dérivés de l'intégrase du vih-1 et compositions
Hollier et al. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function
WO2010091373A8 (fr) Inhibiteurs de fusion du vih pour le traitement ou la prévention de l'infection par le vih
WO2005002501A3 (fr) Nouvelles regions cibles pour des medicaments dans la glycoproteine d'enveloppe du virus de la dengue et procedes d'utilisation associes
WO2004029201A3 (fr) Inhibiteurs de fusion contre l'infection au vih derives de peptides
WO2004070002A3 (fr) Lignees cellulaires et sequences d'acides nucleiques hotes associees a des maladies infectieuses
WO2006077601A3 (fr) Peptides de fusion vih-1 gp41 pour une immunomodulation
WO2001045738A3 (fr) Utilisation de proteines de choc thermique
WO2007002172A3 (fr) Inhibiteurs de la protease du vih-1
WO2010041237A3 (fr) Peptides v3 cycliques pour vaccin anti vih-1
WO2006045616A3 (fr) $g(b)-l-n4-hydroxycytosine desoxynucleosides et leur utilisation comme agents pharmaceutiques dans la prophylaxie ou le traitement de maladies virales
WO2002034909A3 (fr) Chimere de fragments de proteines synthetisee et ses methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005706783

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3468/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580011458.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005706783

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0507949

Country of ref document: BR